Search

Your search keyword '"Zilioli, V"' showing total 87 results
Start Over Author "Zilioli, V"
87 results on '"Zilioli, V"'

2. Primary Mediastinal B‐cell Lymphoma, a nationwide real‐life retrospective study from Fondazione Italiana Linfomi (FIL)

Author

Iannitto, E., primary, Balzarotti, M., additional, Martelli, M., additional, Zinzani, P., additional, Tucci, A., additional, Di Rocco, A., additional, Cavallo, F., additional, Usai, S. V., additional, Guidetti, A., additional, Ravano, E., additional, Merli, F., additional, Botto, B., additional, Pelosini, M., additional, Tecchio, C., additional, Spina, M., additional, Derenzini, E., additional, Finotto, S., additional, Mola, B., additional, Pinto, A., additional, Zanni, E., additional, Battistini, R., additional, Hohaus, S., additional, Dogliotti, I., additional, Gini, G., additional, Zilioli, V. R., additional, De Lorenzo, S., additional, Dodero, A., additional, Broccoli, A., additional, Maggi, A., additional, Mannarella, C., additional, Chiarenza, A., additional, Pastore, D., additional, Cascavilla, N., additional, Musto, P., additional, Stelitano, C., additional, Di Raimondo, F., additional, Di Renzo, N., additional, Liberati, A. M., additional, Salerno, M., additional, Scalone, R., additional, Nassi, L., additional, Patti, C., additional, Polizzi, V., additional, Guarini, A., additional, Amato, G., additional, Ciccone, G., additional, Evangelista, A., additional, Lo Presti, F., additional, La Porta, A., additional, Mannina, D., additional, Calogero, R. D., additional, Musso, M., additional, and Consoli, U., additional

Published
2023
Full Text
View/download PDF

3. FRONTLINE INTENSIFIED ABVD DEMONSTRATES SUPERIOR EFFICACY THAN PET‐ADAPTED ABVD IN ADVANCED HODGKIN LYMPHOMA: THE FIL‐ROUGE PHASE 3 TRIAL BY THE FONDAZIONE ITALIANA LINFOMI

Author

Pinto, A., primary, Corazzelli, G., additional, Evangelista, A., additional, Patti, C., additional, De Lorenzo, S., additional, Re, A., additional, Merli, F., additional, Botto, B., additional, Tarantini, G., additional, Guarini, A., additional, Leonardi, G., additional, Hohaus, S., additional, Cavallo, F., additional, Pulsoni, A., additional, Gotti, M., additional, Celli, M., additional, Gaudio, F., additional, Ricci, F., additional, Liberati, A. M., additional, Pavone, V., additional, Rota‐Scalabrini, D., additional, Flenghi, L., additional, Arcari, A., additional, Cimminiello, M., additional, Zilioli, V. R., additional, Morelli, E., additional, Mulè, A., additional, Arcamone, M., additional, Pagani, C., additional, Arletti, L., additional, Levis, M., additional, De Filippi, R., additional, Cuccaro, A., additional, Cesaretti, M., additional, Borgo, E., additional, Musto, P., additional, Vitolo, U., additional, Chauvie, S., additional, Ricardi, U., additional, Ciccone, G., additional, and Santoro, A., additional

Published
2023
Full Text
View/download PDF

4. Current Treatment Options and the Role of Functional Status Assessment in Classical Hodgkin Lymphoma in Older Adults: A Review

Author

Zilioli, V, Muzi, C, Pagani, C, Ravano, E, Meli, E, Daffini, R, Ravelli, E, Cairoli, R, Re, A, Zilioli, Vittorio Ruggero, Muzi, Cristina, Pagani, Chiara, Ravano, Emanuele, Meli, Erika, Daffini, Rosa, Ravelli, Erika, Cairoli, Roberto, Re, Alessandro, Zilioli, V, Muzi, C, Pagani, C, Ravano, E, Meli, E, Daffini, R, Ravelli, E, Cairoli, R, Re, A, Zilioli, Vittorio Ruggero, Muzi, Cristina, Pagani, Chiara, Ravano, Emanuele, Meli, Erika, Daffini, Rosa, Ravelli, Erika, Cairoli, Roberto, and Re, Alessandro

Abstract

Along with the fact that classical Hodgkin lymphoma (cHL) in older adults is frequently considered biologically different from cHL in younger patients, its most distinctive feature is its dismal clinical outcome due to the decreased effectiveness and greater toxicity of therapies. Although strategies to mitigate specific toxicities (e.g., cardiological and pulmonary) have obtained some results, in general, reduced-intensity schemes, proposed as an alternative to ABVD, have proved to be less effective. The addition of brentuximab vedotin (BV) to AVD, especially in a sequential scheme, has demonstrated good efficacy. However, the problem of toxicity persists even with this new therapeutic combination, with comorbidities remaining an important prognostic factor. The adequate stratification of functional status is necessary to distinguish between those patients who will benefit from full treatment and those who will benefit from alternative strategies. A simplified geriatric assessment based on the determination of ADL (activity of daily living), IADL (instrumental ADL), and CIRS-G (Cumulative Illness Rating Scale—Geriatric) scores is an easy-to-use tool that permits adequate patient stratification. Other factors of considerable impact on functional status such as sarcopenia and immunosenescence are currently being studied. A fitness-based treatment choice would also be very useful for relapsed or refractory patients, a more frequent and challenging situation than that is found in young cHL patients.

Published
2023

5. P1144: RADIOIMMUNOTHERAPY (RIT) VERSUS AUTOLOGOUS HEMATOPOIETIC STEM-CELL TRANSPLANTATION (ASCT) IN RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA: A FONDAZIONE ITALIANA LINFOMI (FIL) PHASE III TRIAL.

Author

Ladetto, M., primary, Tavarozzi, R., additional, Evangelista, A., additional, Zanni, M., additional, Tucci, A., additional, Anastasia, A., additional, Botto, B., additional, Boccomini, C., additional, Bolis, S., additional, Volpetti, S., additional, Zilioli, V. R., additional, Puccini, B., additional, Arcari, A., additional, Pavone, V., additional, Gaidano, G., additional, Corradini, P., additional, Tani, M., additional, Ferrero, S., additional, Cavallo, F., additional, Milone, G., additional, Ghiggi, C., additional, Pinto, A., additional, Pastore, D., additional, Ferreri, A. J., additional, Latte, G., additional, Patti, C., additional, Re, F., additional, Arcaini, L., additional, Benedetti, F., additional, Usai, S. V., additional, Luminari, S., additional, Mannina, D., additional, Pulsoni, A., additional, Stelitano, C., additional, Pennese, E., additional, Pietrantuono, G., additional, Gherlinzoni, F., additional, Pomponi, F., additional, Olivieri, A., additional, Perrone, T., additional, Rota Scalabrini, D., additional, Califano, C., additional, Falini, B., additional, Ciccone, G., additional, and Vitolo, U., additional

Published
2022
Full Text
View/download PDF

6. S221: BORTEZOMIB TO R-DHAP COMPARED TO R-DHAP IN RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA ELIGIBLE TO STEM CELL TRANPLANTATION: FINAL RESULTS OF PHASE II RANDOMIZED FIL-VERAL12

Author

Chiappella, A., primary, Balzarotti, M., additional, Botto, B, additional, Castiglione, A., additional, Cavallo, F., additional, Usai, S. V., additional, Zanni, M., additional, Califano, C., additional, Re, F., additional, Ghiggi, C., additional, Olivieri, A., additional, Corradini, P., additional, Liberati, A. M., additional, Volpetti, S., additional, Michieli, M. G., additional, Tucci, A, additional, Gaidano, G., additional, Tani, M., additional, Ciambelli, F., additional, Musuraca, G., additional, Vallisa, D., additional, Merli, F., additional, Molinari, A. L., additional, Tafuri, A., additional, Zilioli, V. R., additional, Marino, D., additional, Stelitano, C., additional, Pileri, S. A., additional, Ciccone, G., additional, and Vitolo, U., additional

Published
2022
Full Text
View/download PDF

7. Safety and efficacy of NEPA and dexamethasone in Hodgkin's lymphoma patients: a single-center real-life experience

Author

Zilioli, V, Muzi, C, Minga, P, Codega, P, Crucitti, L, Meli, E, Esposito, A, Panico, C, Rusconi, C, Cairoli, R, Zilioli V, Muzi C, Minga P, Codega P, Crucitti L, Meli E, Esposito A, Panico C, Rusconi C, Cairoli R, Zilioli, V, Muzi, C, Minga, P, Codega, P, Crucitti, L, Meli, E, Esposito, A, Panico, C, Rusconi, C, Cairoli, R, Zilioli V, Muzi C, Minga P, Codega P, Crucitti L, Meli E, Esposito A, Panico C, Rusconi C, and Cairoli R

Abstract

We analyzed safety of NEPA (netupitant/palonosetron) and dexamethasone (NEPA+DEX) for the management of chemotherapy-induced nausea and vomiting (CINV) in classical Hodgkin's lymphoma patients that experienced CINV with a prophylaxis with palonosetron (PALO + DEX). In a retrospective, monocentric, noncomparative study, we analyzed adverse events and CINV grading in patients who switched from PALO + DEX to NEPA + DEX. Among 32 patients treated with ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) during the study period, 47% did not properly control CINV with PALO + DEX and were shifted to NEPA + DEX. Among these, 53.3% properly controlled CINV is for all the remaining chemotherapy cycles. We did not observe an increase of adverse events after switching to NEPA. In our study, NEPA did not show drug-drug interaction with ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) chemotherapy agents and NEPA administration was well tolerated with mild and transient adverse events.

Published
2020

8. Decisional Role of Interim PET in Relapsed/Refractory Classical Hodgkin Lymphoma Treated with Begev Chemotherapy As First Salvage

Author

Rusconi, C, Ricci, F, Marasco, V, Zilioli, V, Calabretta, E, Guidetti, A, Muzi, C, Mazzon, F, Smania, M, Sollini, M, Iadecola, S, Meli, E, Rodari, M, Ravano, E, Cairoli, R, Corradini, P, Santoro, A, Zilioli, VR, Rusconi, C, Ricci, F, Marasco, V, Zilioli, V, Calabretta, E, Guidetti, A, Muzi, C, Mazzon, F, Smania, M, Sollini, M, Iadecola, S, Meli, E, Rodari, M, Ravano, E, Cairoli, R, Corradini, P, Santoro, A, and Zilioli, VR

Published
2022

9. Response-Adapted Postinduction Strategy in Patients With Advanced-Stage Follicular Lymphoma: The FOLL12 Study

Author

Luminari, S, Manni, M, Galimberti, S, Versari, A, Tucci, A, Boccomini, C, Farina, L, Olivieri, J, Marcheselli, L, Guerra, L, Ferrero, S, Arcaini, L, Cavallo, F, Kovalchuk, S, Skrypets, T, Del Giudice, I, Chauvie, S, Patti, C, Stelitano, C, Ricci, F, Pinto, A, Margiotta Casaluci, G, Zilioli, V, Merli, A, Ladetto, M, Bolis, S, Pavone, V, Chiarenza, A, Arcari, A, Anastasia, A, Dondi, A, Mannina, D, Federico, M, Luminari, Stefano, Manni, Martina, Galimberti, Sara, Versari, Annibale, Tucci, Alessandra, Boccomini, Carola, Farina, Lucia, Olivieri, Jacopo, Marcheselli, Luigi, Guerra, Luca, Ferrero, Simone, Arcaini, Luca, Cavallo, Federica, Kovalchuk, Sofya, Skrypets, Tetiana, Del Giudice, Ilaria, Chauvie, Stephane, Patti, Caterina, Stelitano, Caterina, Ricci, Francesca, Pinto, Antonello, Margiotta Casaluci, Gloria, Zilioli, Vittorio R, Merli, Anna, Ladetto, Marco, Bolis, Silvia, Pavone, Vincenzo, Chiarenza, Annalisa, Arcari, Annalisa, Anastasia, Antonella, Dondi, Alessandra, Mannina, Donato, Federico, Massimo, Luminari, S, Manni, M, Galimberti, S, Versari, A, Tucci, A, Boccomini, C, Farina, L, Olivieri, J, Marcheselli, L, Guerra, L, Ferrero, S, Arcaini, L, Cavallo, F, Kovalchuk, S, Skrypets, T, Del Giudice, I, Chauvie, S, Patti, C, Stelitano, C, Ricci, F, Pinto, A, Margiotta Casaluci, G, Zilioli, V, Merli, A, Ladetto, M, Bolis, S, Pavone, V, Chiarenza, A, Arcari, A, Anastasia, A, Dondi, A, Mannina, D, Federico, M, Luminari, Stefano, Manni, Martina, Galimberti, Sara, Versari, Annibale, Tucci, Alessandra, Boccomini, Carola, Farina, Lucia, Olivieri, Jacopo, Marcheselli, Luigi, Guerra, Luca, Ferrero, Simone, Arcaini, Luca, Cavallo, Federica, Kovalchuk, Sofya, Skrypets, Tetiana, Del Giudice, Ilaria, Chauvie, Stephane, Patti, Caterina, Stelitano, Caterina, Ricci, Francesca, Pinto, Antonello, Margiotta Casaluci, Gloria, Zilioli, Vittorio R, Merli, Anna, Ladetto, Marco, Bolis, Silvia, Pavone, Vincenzo, Chiarenza, Annalisa, Arcari, Annalisa, Anastasia, Antonella, Dondi, Alessandra, Mannina, Donato, and Federico, Massimo

Abstract

PURPOSE We compared 2 years of rituximab maintenance (RM) with a response-adapted postinduction approach in patients with follicular lymphoma who responded to induction immunochemotherapy. METHODS We randomly assigned treatment-naive, advanced-stage, high-tumor burden follicular lymphoma patients to receive standard RM or a response-adapted postinduction approach on the basis of metabolic response and molecular assessment of minimal residual disease (MRD). The experimental arm used three types of postinduction therapies: for complete metabolic response (CMR) and MRD-negative patients, observation; for CMR and MRD-positive (end of induction or follow-up) patients, four doses of rituximab (one per week, maximum three courses) until MRD-negative; and for non-CMR patients, one dose of ibritumomab tiuxetan followed by standard RM. The study was designed as noninferiority trial with progression-free survival (PFS) as the primary end point. RESULTS Overall, 807 patients were randomly assigned. After a median follow-up of 53 months (range, 1-92 months), patients in the standard arm had a significantly better PFS than those in the experimental arm (3-year PFS 86% v 72%; P < .001). The better PFS of the standard versus experimental arm was confirmed in all the study subgroups except non-CMR patients (n =65; P = .274). The 3-year overall survival was 98% (95% CI, 96 to 99) and 97% (95% CI, 95 to 99) in the reference and experimental arms, respectively (P = .238). CONCLUSION A metabolic and molecular response-adapted therapy as assessed in the FOLL12 study was associated with significantly inferior PFS compared with 2-year RM. The better efficacy of standard RM was confirmed in the subgroup analysis and particularly for patients achieving both CMR and MRDnegative.

Published
2022

10. Safety and efficacy of NEPA and dexamethasone in Hodgkin's lymphoma patients: a single-center real-life experience

Author

Zilioli V, Muzi C, Minga P, Codega P, Crucitti L, Meli E, Esposito A, Panico C, Rusconi C, Cairoli R, Zilioli, V, Muzi, C, Minga, P, Codega, P, Crucitti, L, Meli, E, Esposito, A, Panico, C, Rusconi, C, and Cairoli, R

Subjects
Hodgkin’s lymphoma, CINV, NEPA, ABVD, netupitant, palonosetron
Abstract

We analyzed safety of NEPA (netupitant/palonosetron) and dexamethasone (NEPA+DEX) for the management of chemotherapy-induced nausea and vomiting (CINV) in classical Hodgkin's lymphoma patients that experienced CINV with a prophylaxis with palonosetron (PALO + DEX). In a retrospective, monocentric, noncomparative study, we analyzed adverse events and CINV grading in patients who switched from PALO + DEX to NEPA + DEX. Among 32 patients treated with ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) during the study period, 47% did not properly control CINV with PALO + DEX and were shifted to NEPA + DEX. Among these, 53.3% properly controlled CINV is for all the remaining chemotherapy cycles. We did not observe an increase of adverse events after switching to NEPA. In our study, NEPA did not show drug-drug interaction with ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) chemotherapy agents and NEPA administration was well tolerated with mild and transient adverse events.

Published
2020

11. THE ELDERLY PROGNOSTIC INDEX (EPI) PREDICTS EARLY MORTALITY IN OLDER PATIENTS WITH DLBCL. A SUBSTUDY OF THE ELDERLY PROJECT BY THE FONDAZIONE ITALIANA LINFOMI (FIL)

Author

Merli, F., primary, Tucci, A., additional, Arcari, A., additional, Rigacci, L., additional, Cavallo, F., additional, Cabras, G., additional, Alvarez, I., additional, Fabbri, A., additional, Re, A., additional, Ferrero, S., additional, Puccini, B., additional, Usai, S. V., additional, Ferrari, A., additional, Cencini, E., additional, Pennese, E., additional, Zilioli, V. R., additional, Marino, D., additional, Balzarotti, M., additional, Cox, M. C., additional, Zanni, M., additional, Rocco, A., additional, Lleshi, A., additional, Botto, B., additional, Hohaus, S., additional, Merli, M., additional, Sartori, R., additional, Gini, G., additional, Nassi, L., additional, Musuraca, G., additional, Tani, M., additional, Bottelli, C., additional, Kovalchuk, S., additional, Re, F., additional, Flenghi, L., additional, Molinari, A., additional, Tarantini, G., additional, Chimienti, E., additional, Marcheselli, L., additional, Mammi, C., additional, Luminari, S., additional, and Spina, M., additional

Published
2021
Full Text
View/download PDF

12. BRENTUXIMAB VEDOTIN CONSOLIDATION AFTER AUTOLOGOUS STEM CELLS TRANSPLANTATION FOR HODGKIN LYMPHOMA: A REAL‐LIFE EXPERIENCE BY FONDAZIONE ITALIANA LINFOMI (FIL)

Author

Massaro, F., primary, Pavone, V., additional, Stefani, P. M., additional, Botto, B., additional, Pulsoni, A., additional, Patti, C., additional, Cantonetti, M., additional, Visentin, A., additional, Scalzulli, P. R., additional, Rossi, A., additional, Galimberti, S., additional, Cimminiello, M., additional, Gini, G., additional, Musso, M., additional, Sorio, M., additional, Arcari, A., additional, Zilioli, V. R., additional, Bari, A., additional, Mannina, D., additional, Fabbri, A., additional, Pietrantuono, G., additional, Annibali, O., additional, Tafuri, A., additional, Prete, E., additional, Mulè, A., additional, Barbolini, E., additional, Marcheselli, L., additional, Luminari, S., additional, and Merli, F., additional

Published
2021
Full Text
View/download PDF

13. SARCOPENIA IS AN INDEPENDENT PROGNOSTIC FACTOR IN ELDERLY MALE PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA: RESULTS FROM A MULTICENTER EXPERIENCE

Author

Zilioli, V. R., primary, Albano, D., additional, Arcari, A., additional, Merli, F., additional, Coppola, A., additional, Besutti, G., additional, Marcheselli, L., additional, Gramegna, D., additional, Muzi, C., additional, Manicone, M., additional, Camalori, M., additional, Ciammella, P., additional, Colloca, G., additional, and Tucci, A., additional

Published
2021
Full Text
View/download PDF

14. IMPACT OF DIFFERENT INDUCTION REGIMENS ON THE OUTCOME OF PRIMARY MEDIASTINAL B CELL LYMPHOMA IN THE PROSPECTIVE IELSG 37 TRIAL

Author

Martelli, M., primary, Zucca, E., additional, Botto, B., additional, Kryachok, I., additional, Ceriani, L., additional, Balzarotti, M., additional, Tucci, A., additional, Cabras, M. G., additional, Zilioli, V. R., additional, Rusconi, C., additional, Angrilli, F., additional, Arcaini, L., additional, Iwanicka, A. Dabrowska, additional, Ferreri, A.J.M., additional, Merli, F., additional, Zhao, W., additional, Hodgson, D., additional, Ionescu, C., additional, Fosså, A., additional, Cwynarski, K., additional, Mikhaeel, G., additional, Jerkeman, M., additional, Janikova, A., additional, Hüttmann, A., additional, Ciccone, G., additional, Metser, U., additional, Barrington, S., additional, Malkowski, B., additional, Versari, A., additional, Esposito, F., additional, Cozens, K., additional, Ielmini, N., additional, Ricardi, R., additional, Cavalli, F., additional, Johnson, P., additional, and Davies, A., additional

Published
2021
Full Text
View/download PDF

15. UPDATED RESULTS OF THE FIL “MIRO” STUDY, A MULTICENTER PHASE II TRIAL COMBINING LOCAL RADIOTHERAPY AND MRD‐DRIVEN IMMUNOTHERAPY IN EARLY‐STAGE FOLLICULAR LYMPHOMA

Author

Pulsoni, A., primary, Tosti, M. E., additional, Ferrero, S., additional, Luminari, S., additional, Dondi, A., additional, Liberati, A. M., additional, Cenfra, N., additional, Renzi, D., additional, Zanni, M., additional, Boccomini, C., additional, Ferreri, A. J., additional, Rattotti, S., additional, Zilioli, V. R., additional, Bernuzzi, P., additional, Bolis, S., additional, Musuraca, G., additional, Nassi, L., additional, Perrone, T., additional, Stelitano, C., additional, Anastasia, A., additional, Corradini, P., additional, Partesotti, G., additional, Re, F., additional, Cencini, E., additional, Mannarella, C., additional, Mannina, D., additional, Molinari, A. L., additional, Tani, M., additional, Annechini, G., additional, Assanto, G. M., additional, Grapulin, L., additional, Guarini, A., additional, Cavalli, M., additional, De Novi, L. A., additional, Ciabatti, E., additional, Mantoan, B., additional, Della Starza, I., additional, Arcaini, L., additional, Ricardi, U., additional, Gattei, V., additional, Galimberti, S., additional, Ladetto, M., additional, Foà, R., additional, and Del Giudice, I., additional

Published
2021
Full Text
View/download PDF

16. AUTOLOGOUS TRANSPLANT IN ELDERLY PATIENTS WITH R/R AGGRESSIVE LYMPHOMA SELECTED BY SIMPLIFIED CGA: THE RECANZ PROSPECTIVE PHASE 2 STUDY BY THE FONDAZIONE ITALIANA LINFOMI

Author

Tucci, A, primary, Musuraca, G, additional, Cavallo, F, additional, Zilioli, V. R, additional, Zanni, M, additional, Pelliccia, S, additional, Mannina, D, additional, Michieli, M, additional, Vallisa, D, additional, Tani, M, additional, Merli, F, additional, Re, F, additional, Marcheselli, L, additional, Campostrini, G, additional, Pagani, C, additional, Grimaldi, D, additional, Liardo, E. V, additional, Re, A, additional, Cox, M. C, additional, and Rossi, G, additional

Published
2021
Full Text
View/download PDF

17. ROMIDEPSIN‐CHOEP PLUS UP‐FRONT STEM‐CELL TRANSPLANTATION IN PERIPHERAL T‐CELL LYMPHOMA (PTCL): FIRST ANALYSIS OF THE PHASE II FIL‐PTCL13 STUDY

Author

Chiappella, A., primary, Carniti, C., additional, Re, A., additional, Castellino, C., additional, Evangelista, A., additional, Ciancia, R., additional, Orsucci, L., additional, Pinto, A., additional, Usai, S. V., additional, Arcari, A., additional, Ilariucci, F., additional, Rossi, F. G., additional, Benedetti, F., additional, Flenghi, L., additional, Ghiggi, C., additional, Molinari, A. L., additional, Stefoni, V., additional, Volpetti, S., additional, Zilioli, V. R., additional, Ballerini, F., additional, Bruna, R., additional, Cavallo, F., additional, Musuraca, G., additional, Patti, C., additional, Re, F., additional, Tani, M., additional, Varettoni, M., additional, Zanni, M., additional, Dodero, A., additional, Pileri, S. A., additional, Ciccone, G., additional, and Corradini, P., additional

Published
2021
Full Text
View/download PDF

18. DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) IN LATE‐OCTOGENARIAN (LO) PATIENTS: A SUBSTUDY OF THE “ELDERLY PROJECT” BY THE FONDAZIONE ITALIANA LINFOMI (FIL)

Author

Tucci, A., primary, Merli, F., additional, Fabbri, A., additional, Mancuso, S., additional, Sartori, R., additional, Storti, S., additional, Luminari, S., additional, Mammi, C., additional, Marcheselli, L., additional, Arcari, A., additional, Cavallo, F., additional, Zilioli, V. R., additional, Bottelli, C., additional, Re, A., additional, Gini, G., additional, Cox, M. C., additional, Puccini, B., additional, Pagani, C., additional, Balzarotti, M., additional, Spina, M., additional, and Rossi, G., additional

Published
2021
Full Text
View/download PDF

19. Feasibility of all-oral anti-HCV treatment during DHAP chemotherapy and autologous stem cell transplantation for T-cell lymphoma

Author

Rossotti, R, Rusconi, C, Baiguera, C, Zilioli, V, Grillo, G, Merli, M, Ravano, E, Puoti, M, Rossotti R., Rusconi C., Baiguera C., Zilioli V. R., Grillo G., Merli M., Ravano E., Puoti M., Rossotti, R, Rusconi, C, Baiguera, C, Zilioli, V, Grillo, G, Merli, M, Ravano, E, Puoti, M, Rossotti R., Rusconi C., Baiguera C., Zilioli V. R., Grillo G., Merli M., Ravano E., and Puoti M.

Abstract

The role of anti-HCV direct-acting agents (DAAs) is well described in HCV-related lymphoproliferative disorders, whereas few data are available on their use in other Malignancies, such as aggressive T-cell lymphomas requiring autologous stem cell transplantation (ASCT). We describe two oncologic cirrhotic patients treated with DAAs who underwent ASCT achieving cure for both diseases. Co-administration of sofosbuvir with cisplatin led an unexpected severe kidney impairment that did not resolve 30 weeks after drug exposure. The optimal timing of DAA administration in the ASCT setting has yet to be defined: our experience shows that co-administration is feasible, but requires close monitoring for adverse events.

Published
2018

21. LENALIDOMIDE AND RITUXIMAB (ReRi) AS FRONT LINE THERAPY OF ELDERLY FRAIL PATIENTS WITH DIFFUSE LARGE B-CELLS LYMPHOMA. FIRST PLANNED INTERIM ANALYSIS OF A PHASE II STUDY OF THE FONDAZIONE ITALIANA LINFOMI (FIL)

Author

Gini, G., primary, Tani, M., additional, Bassan, R., additional, Tucci, A., additional, Ballerini, F., additional, Sampaolo, M., additional, Merli, F., additional, Re, F., additional, Annibali, O., additional, Liberati, A., additional, Visco, C., additional, Arcari, A., additional, Storti, S., additional, Fabbri, A., additional, Musuraca, G., additional, Zilioli, V., additional, Cox, M., additional, and Luminari, S., additional

Published
2019
Full Text
View/download PDF

23. Attenuation correction in myocardial perfusion imaging affects the assessment of infarct size in women with previous inferior infarct

Author

Peli, A, Camoni, L, Zilioli, V, Durmo, R, Bonacina, M, Bertagna, F, Paghera, B, Giubbini, R, Peli, Alessia, Camoni, Luca, ZILIOLI, VALENTINA, Durmo, Rexhep, Bonacina, Mattia, Bertagna, Francesco, Paghera, Barbara, Giubbini, Raffaele, Peli, A, Camoni, L, Zilioli, V, Durmo, R, Bonacina, M, Bertagna, F, Paghera, B, Giubbini, R, Peli, Alessia, Camoni, Luca, ZILIOLI, VALENTINA, Durmo, Rexhep, Bonacina, Mattia, Bertagna, Francesco, Paghera, Barbara, and Giubbini, Raffaele

Abstract

Background Myocardial perfusion imaging is a well-established diagnostic tool in patients with known or suspected coronary artery disease. Numerous clinical trials have shown that attenuation correction (AC) in single photon emission computed tomography (SPECT) improves the diagnostic accuracy of myocardial perfusion imaging over non-AC SPECT, differentiating between scar and attenuation artifacts. We have previously shown that attenuation artifacts produce an overestimation of the size of inferior infarcts in the male population. It is assumed that women are less affected by inferior attenuation artifacts than men. Purpose The aim of this study is to evaluate the role of AC in the assessment of infarct size in female patients with a history of myocardial inferior infarct. Patients and methods We studied a population of 66 consecutive women, with a history of previous inferior myocardial infarct, by SPECT/computed tomography (CT) with 370+370 MBq of technetium-99m labeled compounds by a 2-day stress-rest protocol. Both AC and uncorrected gated-SPECT/CT studies were reconstructed after scatter and motion correction by ordered-subset expectation maximization iterative reconstruction and resolution recovery. The coregistration of the transmission and emission scans was verified for all patients; any misalignment was realigned manually. Uncorrected and corrected SPECT images were analyzed by software QPS/QGS package using a 17-segment model. For each segment, perfusion and wall motion were quantified using a five-point score according to the American Society of Nuclear Cardiology guidelines. Summed stress, summed rest score (SRS), and summed difference score of the inferior left ventricle wall (inferior, inferoseptal, inferolateral, and apical inferior segments) were calculated. A linear correlation was used to assess the relationship between perfusion and the regional wall motion score as determined by uncorrected gated-SPECT. Results The results of quantitative analys

Published
2018

26. Flow cytometry analysis of lymphocyte subsets in bronchoalveolar lavage: comparison between lung non-Hodgkin lymphomas and reactive diseases

Author

Cesana, C, Scarpati, B, Brando, B, Scampini, L, Liga, G, Klersy, C, Chiericozzi, M, Zilioli, V, Rusconi, C, Nichelatti, M, Fieschi, S, Torre, M, Vanzulli, A, Cairoli, R, Rossini, S, Cesana C, Scarpati B, Brando B, Scampini L, Liga G, Klersy C, Chiericozzi M, Zilioli VR, Rusconi C, Nichelatti M, Fieschi S, Torre M, Vanzulli A, Cairoli R, Rossini S., Cesana, C, Scarpati, B, Brando, B, Scampini, L, Liga, G, Klersy, C, Chiericozzi, M, Zilioli, V, Rusconi, C, Nichelatti, M, Fieschi, S, Torre, M, Vanzulli, A, Cairoli, R, Rossini, S, Cesana C, Scarpati B, Brando B, Scampini L, Liga G, Klersy C, Chiericozzi M, Zilioli VR, Rusconi C, Nichelatti M, Fieschi S, Torre M, Vanzulli A, Cairoli R, and Rossini S.

Abstract

Deepened flow cytometry (FCM) analysis of bronchoalveolar lavage fluid (BALF) cells can disclose clonal B and abnormal T lymphocytes in case of lung involvement in non Hodgkin lymphoma (NHL). The possible role of routine FCM BALF analysis in diagnosing NHL involving the lungs is largely undetermined. To evaluate whether differences exist, within FCM screening of lymphocyte subsets, between BALFs from lung NHL and BALFs from reactive diseases. We compared alveolar leukocyte and lymphocyte data obtained using flow cytometry in 17 lung NHL cases with the median corresponding data detected in 208 controls, matched with cases for computed tomography findings. Absolute leukocyte counts did not differ significantly between cases and controls. As calculated within leukocytes, percentages of total, B, T, CD4+ and CD8+ T lymphocytes, respectively, were significantly higher in B cell NHL cases than in their controls (P = .003,.023,.009,.004, and.020, respectively). Similarly, percentages of total, and CD8+ T lymphocytes, respectively, were significantly higher in T cell NHL cases than in their controls (P = .046 and.027, respectively). Huger BALF lymphocytosis occurs in pulmonary NHLs than in other lung diseases. Possible lymphocyte cutoffs, that could indicate lung NHL and the subsequent need of a second-step BALF staining shortly following the initial screening, should be prospectively attempted.

Published
2017

32. PRIMARY CARDIAC LYPHOMA: CLINICAL MANAGEMENT OF A RARE ENTITY

Author

Zancanella, M, Rusconi, C, Moreo, A, Zilioli, V, Greco, A, Minga, P, Meli, E, Sormani, P, Cairoli, R, Zancanella M, Rusconi C, Moreo A, Zilioli VR, Greco A, Minga P, Meli E, Sormani P, Cairoli R, Zancanella, M, Rusconi, C, Moreo, A, Zilioli, V, Greco, A, Minga, P, Meli, E, Sormani, P, Cairoli, R, Zancanella M, Rusconi C, Moreo A, Zilioli VR, Greco A, Minga P, Meli E, Sormani P, and Cairoli R

Published
2015

33. Outcome of Transformed Marginal Zone Lymphomas Treated in the Rituximab Era

Author

Rusconi, C, Guerrera, M, Tedeschi, A, Zancanella, M, Gotti, M, Nichelatti, M, Rattotti, S, Crucitti, L, Frigeni, M, Meli, E, Picardi, P, Frustaci, A, Sciarra, R, Zilioli, V, Minga, P, Paulli, M, Cairoli, R, Arcaini, L, Guerrera, ML, Frustaci, AM, Zilioli, VR, Rusconi, C, Guerrera, M, Tedeschi, A, Zancanella, M, Gotti, M, Nichelatti, M, Rattotti, S, Crucitti, L, Frigeni, M, Meli, E, Picardi, P, Frustaci, A, Sciarra, R, Zilioli, V, Minga, P, Paulli, M, Cairoli, R, Arcaini, L, Guerrera, ML, Frustaci, AM, and Zilioli, VR

Published
2015

42. The “Elderly Project” by the Fondazione Italiana Linfomi (FIL): a prospective multidimensional assessment of elderly patients with diffuse large B-cell lymphoma

Author

Merli, F., primary, Tucci, A., additional, Angrilli, F., additional, Cavallo, F., additional, Cabras, G., additional, Fabbri, A., additional, Mammi, C., additional, Chiappella, A., additional, Gussetti, D., additional, Zilioli, V., additional, Arcari, A., additional, Tani, M., additional, Balzarotti, M., additional, Fedina, A., additional, Marcheselli, L., additional, and Spina, M., additional

Published
2015
Full Text
View/download PDF

43. Poster session V * Saturday 11 December 2010, 08:30-12:30

Author

Pham, Q. H., primary, Von Lueder, T. G., additional, Namtvedt, S. K., additional, Rosjo, H., additional, Omland, T., additional, Steine, K., additional, Timoteo, A. T., additional, Mota Carmo, M., additional, Simoes, M., additional, Branco, L. M., additional, Ferreira, R. C., additional, Kato, R., additional, Ito, J., additional, Tahara, T., additional, Yokoyama, Y., additional, Ashikaga, T., additional, Satoh, Y., additional, Na, J. O., additional, Hong, H. E., additional, Kim, M. N., additional, Shin, S. Y., additional, Choi, C. U., additional, Kim, E. J., additional, Rha, S. W., additional, Park, C. G., additional, Seo, H. S., additional, Oh, D. J., additional, Ticulescu, R., additional, Brigido, S., additional, Vriz, O., additional, Sparacino, L., additional, Popescu, B. A., additional, Ginghina, C., additional, Carerj, S., additional, Nicolosi, G. L., additional, Antonini-Canterin, F., additional, Onaindia Gandarias, J. J., additional, Romero, A., additional, Laraudogoitia, E., additional, Velasco, S., additional, Quintana, O., additional, Cacicedo, A., additional, Rodriguez, I., additional, Alarcon, J. A., additional, Gonzalez, J., additional, Lekuona, I., additional, Subinas, A., additional, Abdula, G., additional, Lund, L. H., additional, Winter, R., additional, Brodin, L., additional, Sahlen, A., additional, Masaki, M., additional, Cha, Y. M., additional, Yuasa, T., additional, Dong, K., additional, Dong, Y. X., additional, Mankad, S. V., additional, Oh, J. K., additional, Vallet, F., additional, Lequeux, B., additional, Diakov, C., additional, Sosner, P., additional, Christiaens, L., additional, Coisne, D., additional, Kihara, C., additional, Murata, K., additional, Wada, Y., additional, Uchida, K., additional, Ueyama, T., additional, Okuda, S., additional, Susa, T., additional, Matsuzaki, M., additional, Cho, E. J., additional, Choi, K. Y., additional, Kwon, B. J., additional, Kim, D. B., additional, Jang, S. W., additional, Cho, J. S., additional, Jung, H. O., additional, Jeon, H. K., additional, Youn, H. J., additional, Kim, J. H., additional, Cikes, M., additional, Bijnens, B., additional, Velagic, V., additional, Kopjar, T., additional, Milicic, D., additional, Biocina, B., additional, Gasparovic, H., additional, Almuntaser, I., additional, Brown, A., additional, Foley, B., additional, Mulvihill, N., additional, Crean, P., additional, King, G., additional, Murphy, R., additional, Takata, Y., additional, Taniguchi, M., additional, Nobusada, S., additional, Sugawara, M., additional, Toh, N., additional, Kusano, K., additional, Itoh, H., additional, Wellnhofer, E., additional, Kriatselis, C., additional, Nedios, S., additional, Gerds-Li, J. H., additional, Fleck, E., additional, Poulsen, M. K., additional, Henriksen, J. E., additional, Dahl, J., additional, Johansen, A., additional, Haghfelt, T., additional, Hoilund-Carlsen, P. F., additional, Beck-Nielsen, H., additional, Moller, J. E., additional, Dankowski, R., additional, Wierzchowiecki, M., additional, Michalski, M., additional, Nowicka, A., additional, Szymanowska, K., additional, Pajak, A., additional, Poprawski, K., additional, Szyszka, A., additional, Kasner, M., additional, Westermann, D., additional, Schultheiss, H. P., additional, Tschoepe, C., additional, Watanabe, T., additional, Iwai-Takano, M., additional, Kobayashi, A., additional, Machii, H., additional, Takeishi, Y., additional, Paelinck, B. P., additional, Van Herck, P. L., additional, Bosmans, J. M., additional, Vrints, C. J., additional, Lamb, H. J., additional, Doltra, A., additional, Vidal, B., additional, Silva, E., additional, Poyatos, S., additional, Mont, L., additional, Berruezo, A., additional, Castel, A., additional, Tolosana, J. M., additional, Brugada, J., additional, Sitges, M., additional, Dencker, M., additional, Bjorgell, O., additional, Hlebowicz, J., additional, Szelenyi, Z. S., additional, Szenasi, G., additional, Kiss, M., additional, Prohaszka, Z., additional, Patocs, A., additional, Karadi, I., additional, Vereckei, A., additional, Saha, S. K., additional, Anderson, P. L., additional, Govind, S., additional, Govindan, M., additional, Moggridge, J. C., additional, Kiotsekoglou, A., additional, Gopal, A. S., additional, Loegstrup, B. B., additional, Christophersen, T. B., additional, Hoefsten, D. E., additional, Moeller, J. E., additional, Boetker, H. E., additional, Egstrup, K., additional, Graefe, M., additional, Huang, F. Q., additional, Zhang, R. S., additional, Le, T. T., additional, Tan, R. S., additional, Sattarzadeh Badkoubeh, R., additional, Tavoosi, A., additional, Elahian, A. R., additional, Drapkina, O., additional, Ivashkin, V. I., additional, Fazakas, A., additional, Pepo, L., additional, Janosi, O., additional, Kopitovic, I., additional, Goncalves, A., additional, Marcos-Alberca, P., additional, Almeria, C., additional, Feltes, G., additional, Rodriguez, E., additional, Garcia, E., additional, Hernandez-Antolin, R., additional, Macaya, C., additional, Silva Cardoso, J., additional, Zamorano, J. L., additional, Navarro, M. S., additional, Valentin, M., additional, Banes, C. M., additional, Rigo, F., additional, Grolla, E., additional, Tona, F., additional, Cuaia, V., additional, Moreo, A., additional, Badano, L., additional, Raviele, A., additional, Iliceto, S., additional, Tarzia, P., additional, Sestito, A., additional, Nerla, R., additional, Di Monaco, A., additional, Infusino, F., additional, Matera, D., additional, Greco, F., additional, Tacchino, R. M., additional, Lanza, G. A., additional, Crea, F., additional, Nemes, A., additional, Balazs, E., additional, Pinter, K. S., additional, Egyed, A., additional, Csanady, M., additional, Forster, T., additional, Holte, E., additional, Vegsundvag, J., additional, Hole, T., additional, Hegbom, K., additional, Wiseth, R., additional, Sharif, D., additional, Sharif-Rasslan, A., additional, Shahla, C., additional, Khalil, A., additional, Rosenschein, U., additional, Zagatina, A., additional, Zhuravskaya, N., additional, Tyurina, T. V., additional, Tagliamonte, E., additional, Cirillo, T., additional, Coppola, A., additional, Marinelli, U., additional, Romano, C., additional, Riccio, G., additional, Citro, R., additional, Astarita, C., additional, Capuano, N., additional, Quaranta, G., additional, Desiderio, A., additional, Frattini, S., additional, Faggiano, P., additional, Zilioli, V., additional, Locantore, E., additional, Longhi, S., additional, Bellandi, F., additional, Faden, G., additional, Triggiani, M., additional, Dei Cas, L., additional, Dalsgaard, M., additional, Kjaergaard, J., additional, Iversen, K., additional, Hassager, C., additional, Dinh, W., additional, Nickl, W. N., additional, Smettan, J. S., additional, Koehler, T. K., additional, Scheffold, T. D., additional, Coll Barroso, M. C. B., additional, Guelker, J. G., additional, Fueth, R. F., additional, Kamperidis, V., additional, Hadjimiltiades, S., additional, Sianos, G., additional, Efthimiadis, G., additional, Karvounis, H., additional, Parcharidis, G., additional, Styliadis, I. H., additional, Velasco Del Castillo, M. S., additional, Onaindia, J. J., additional, Telleria, M., additional, Carstensen, H. G., additional, Nordenberg, C., additional, Sogaard, P., additional, Fritz-Hansen, T., additional, Bech, J., additional, Galatius, S., additional, Jensen, J. S., additional, Mogelvang, R., additional, Bartko, P. E., additional, Graf, S., additional, Rosenhek, R., additional, Burwash, I. G., additional, Bergler-Klein, J., additional, Clavel, M.-A., additional, Baumgartner, H., additional, Pibarot, P., additional, Mundigler, G., additional, Kirilmaz, B., additional, Eser, I., additional, Tuzun, N., additional, Komur, B., additional, Dogan, H., additional, Taskiran Comez, A., additional, Ercan, E., additional, Cusma-Piccione, M., additional, Zito, C., additional, Oreto, G., additional, Piluso, S., additional, Tripepi, S., additional, Oreto, L., additional, Longordo, C., additional, Ciraci, L., additional, Di Bella, G., additional, Piatkowski, R., additional, Kochanowski, J., additional, Scislo, P., additional, Grabowski, M., additional, Marchel, M., additional, Roik, M., additional, Kosior, D., additional, Opolski, G., additional, Sknouril, L., additional, Dorda, M., additional, Holek, B., additional, Gajdusek, L., additional, Chovancik, J., additional, Branny, M., additional, Fiala, M., additional, Szymanski, P., additional, Lipczynska, M., additional, Klisiewicz, A., additional, Hoffman, P., additional, Jander, N., additional, Minners, J., additional, Martin, G., additional, Zeh, W., additional, Allgeier, M., additional, Gohlke-Baewolf, C., additional, Gohlke, H., additional, Nistri, S., additional, Porciani, M. C., additional, Attanasio, M., additional, Abbate, R., additional, Gensini, G. F., additional, Pepe, G., additional, Duncan, R. F., additional, Piantadosi, C., additional, Nelson, A. J., additional, Wittert, G., additional, Dundon, B., additional, Worthley, M. I., additional, Worthley, S. G., additional, Jung, P., additional, Berlinger, K., additional, Rieber, J., additional, Sohn, H. Z., additional, Schneider, P., additional, Leibig, M., additional, Koenig, A., additional, Klauss, V., additional, Tomkiewicz-Pajak, L., additional, Kolcz, J., additional, Olszowska, M., additional, Pieculewicz, M., additional, Podolec, P., additional, Przewlocki, T., additional, Suchon, E., additional, Sobien, B., additional, Wilkolek, P., additional, Ziembicka, A., additional, Hlawaty, M., additional, Van De Bruaene, A., additional, Hermans, H., additional, Buys, R., additional, Vanhees, L., additional, Delcroix, M., additional, Voigt, J.-U., additional, Budts, W., additional, De Cillis, E., additional, Acquaviva, T., additional, Basile, D., additional, Bortone, A. S., additional, Kalimanovska-Ostric, D., additional, Nastasovic, T., additional, Vujisic-Tesic, B., additional, Jovanovic, I., additional, Milakovic, B., additional, Dostanic, M., additional, Stosic, M., additional, Frogoudaki, A., additional, Andreou, K., additional, Parisis, J., additional, Triantafyllidi, E., additional, Gaitani, S., additional, Paraskevaidis, J., additional, Anastasiou-Nana, M., additional, De Pasquale, G., additional, Kuehn, A., additional, Petzuch, K., additional, Mueller, J., additional, Meierhofer, C., additional, Fratz, S., additional, Hager, A., additional, Hess, J., additional, Vogt, M., additional, Attenhofer Jost, C. H., additional, Dearani, J. A., additional, Scott, C. G., additional, Burkhart, H. M., additional, Connolly, H. M., additional, Vitarelli, A., additional, Battaglia, D., additional, Caranci, F., additional, Padella, V., additional, Continanza, G., additional, Dettori, O., additional, Capotosto, L., additional, Vitarelli, M., additional, De Cicco, V., additional, Cortez Morichetti, M., additional, Mohanan Nair, K. K., additional, Sasidaharan, B., additional, Thajudeen, A., additional, Tharakan, J. M., additional, Mertens, L., additional, Ahmad, N., additional, Kantor, P. K., additional, Grosse-Wortmann, L., additional, Friedberg, M. K., additional, Bernard, Y. F., additional, Morel, M. A., additional, Descotes-Genon, V., additional, Jehl, J., additional, Meneveau, N., additional, Schiele, F., additional, Kaldararova, M., additional, Simkova, I., additional, Tittel, P., additional, Masura, J., additional, Trojnarska, O., additional, Szczepaniak, L., additional, Mizia -Stec, K., additional, Cieplucha, A., additional, Bartczak, A., additional, Grajek, S., additional, Tykarski, A., additional, Gasior, Z., additional, Babovicvuksanovic, D., additional, Bonnichsen, C. R., additional, Morgan, G. J., additional, Slorach, C., additional, Hui, W., additional, Sarkola, T., additional, Lee, K. J., additional, Chaturvedi, R., additional, Benson, L., additional, Bradley, T., additional, Iancu, M. E., additional, Ghiorghiu, I., additional, Serban, M., additional, Craciunescu, I., additional, Hodo, A., additional, Morgan, J., additional, Roche, L., additional, Lee, K., additional, Milanesi, O., additional, Favero, V., additional, Padalino, M., additional, Biffanti, R., additional, Cerutti, A., additional, Maschietto, N., additional, Reffo, E., additional, Vida, V., additional, Stellin, G., additional, Irtyuga, O., additional, Gamazin, D., additional, Voronkina, I., additional, Tsoyi, N., additional, Gudkova, E., additional, Moiseeva, O., additional, Aggeli, C., additional, Kazazaki, C., additional, Felekos, I., additional, Lagoudakou, S., additional, Roussakis, G., additional, Skoumas, J., additional, Pitsavos, C., additional, Stefanadis, C., additional, Cueff, C., additional, Keenan, N., additional, Steg, P. G., additional, Cimadevilla, C., additional, Ducrocq, G., additional, Vahanian, A., additional, Messika-Zeitoun, D., additional, Petrella, L., additional, Mazzola, A. M., additional, Villani, C. V., additional, Giancola, R. G., additional, Ciocca, M. C., additional, Di Eusanio, D. E. M., additional, Nolan, S., additional, Ionescu, A., additional, Skaug, T. R., additional, Amundsen, B. H., additional, Hergum, T., additional, Torp, H., additional, Haugen, B. O., additional, Lopez Aguilera, J., additional, Mesa Rubio, D., additional, Ruiz Ortiz, M., additional, Delgado Ortega, M., additional, Villanueva Fernandez, E., additional, Cejudo Diaz Del Campo, L., additional, Toledano Delgado, F., additional, Leon Del Pino, M., additional, Romo Pena, E., additional, Suarez De Lezo Cruz-Conde, J., additional, De Marco, E., additional, Colucci, A., additional, Comerci, G., additional, Gabrielli, F. A., additional, Natali, R., additional, Garramone, B., additional, Savino, M., additional, Lotrionte, M., additional, Sonaglioni, A., additional, Loperfido, F., additional, Zdravkovic, M., additional, Perunicic, J., additional, Krotin, M., additional, Ristic, M., additional, Vukomanovic, V., additional, Zaja, M., additional, Radovanovic, S., additional, Saric, J., additional, Zdravkovic, D., additional, Cotrim, C., additional, Almeida, A. R., additional, Miranda, R., additional, Almeida, A. G., additional, Picano, E., additional, Carrageta, M., additional, D'andrea, A., additional, Cocchia, R., additional, Riegler, L., additional, Golia, E., additional, Scarafile, R., additional, Caso, P., additional, Russo, M. G., additional, Bossone, E., additional, Calabro', R., additional, Noman, H., additional, Adel, A., additional, Elfaramawy, A. M. R., additional, Abdelraouf, M., additional, Elnaggar, W. A. E. L., additional, Baligh, E., additional, Sargento, L., additional, Silva, D., additional, Goncalves, S., additional, Ribeiro, S., additional, Vinhas Sousa, G., additional, Almeida, A., additional, Lopes, M., additional, Rodriguez-Manero, M., additional, Aguado Gil, L., additional, Azcarate, P., additional, Lloret Luna, P., additional, Macias Gallego, A., additional, Castano, S. A. R. A., additional, Garcia, M., additional, Pujol Salvador, C., additional, Barba, J., additional, Redondo, P., additional, Tomasoni, L., additional, Sitia, S., additional, Atzeni, F., additional, Gianturco, L., additional, Ricci, C., additional, Sarzi-Puttini, P., additional, Turiel, M., additional, De Gennaro Colonna, V., additional, Uejima, T., additional, Jaroch, J., additional, Polombo, C., additional, Hughes, A., additional, Vinereanu, D., additional, Evanvelista, A., additional, Leftheriotis, G., additional, Fraser, A. G., additional, Lewczuk, A., additional, Sobkowicz, B., additional, Tomaszuk-Kazberuk, A., additional, Sawicki, R., additional, Hirnle, T., additional, Michalski, B. W., additional, Filipiak, D., additional, Kasprzak, J. D., additional, Lipiec, P., additional, Dalen, H., additional, Mjolstad, O. C., additional, Klykken, B. E., additional, Graven, T., additional, Martensson, M., additional, Olsson, M., additional, Brodin, L.-A., additional, Enache, R., additional, Leiballi, E., additional, Penhall, A., additional, Perry, R., additional, Altman, M., additional, Sinhal, A., additional, Bennetts, J., additional, Chew, D. P., additional, Joseph, M. X., additional, Larsen, L. H., additional, Kristensen, T., additional, Kober, L. V., additional, Kofoed, K. F., additional, Moscoso Costa, F., additional, Ribeiras, R., additional, Brito, J., additional, Boshoff, S., additional, Neves, J., additional, Teles, R., additional, Canada, M., additional, Andrade, M. J., additional, Gouveia, R., additional, Silva, A., additional, Miskovic, A., additional, Poerner, T. P., additional, Stiller, C. S., additional, Goebel, B. G., additional, Moritz, A. M., additional, Stefani, L., additional, Galanti, G. G., additional, Moraldo, M., additional, Bergamini, C., additional, Pabari, P. A., additional, Dhutia, N. M., additional, Malaweera, A. S. N., additional, Willson, K., additional, Davies, J., additional, Hughes, A. D., additional, Xu, X. Y., additional, Francis, D. P., additional, Jasaityte, R., additional, Amundsen, B., additional, Barbosa, D., additional, Loeckx, D., additional, Kiss, G., additional, Orderud, F., additional, Robesyn, V., additional, Claus, P., additional, D'hooge, J., additional, Nao, T., additional, Miura, T., additional, Shams, K., additional, Samir, S., additional, Samir, R., additional, El-Sayed, M., additional, Anwar, A. M., additional, Nosir, Y., additional, Galal, A., additional, Chamsi-Pasha, H., additional, Ciobanu, A., additional, Dulgheru, R., additional, Bennett, S., additional, De Luca, A., additional, Toncelli, L., additional, Cappelli, F., additional, Cappelli, B., additional, Vono, M. C. R., additional, Galanti, G., additional, Zorman, Y., additional, Yilmazer, M. S., additional, Akyildiz, M., additional, Gurol, T., additional, Aydin, A., additional, Dagdeviren, B., additional, and Kalangos, A., additional

Published
2010
Full Text
View/download PDF

44. Poster session III * Friday 10 December 2010, 08:30-12:30

Author

Guldbrand, D., primary, Goetzsche, O., additional, Eika, B., additional, Watanabe, N., additional, Taniguchi, M., additional, Akagi, T., additional, Koide, N., additional, Sano, S., additional, Orbovic, B., additional, Obrenovic-Kircanski, B., additional, Ristic, S., additional, Soskic, L. J., additional, Alhabshan, F., additional, Jijeh, A., additional, Abo Remsh, H., additional, Alkhaldi, A., additional, Najm, H. K., additional, Gasior, Z., additional, Skowerski, M., additional, Kulach, A., additional, Szymanski, L., additional, Sosnowski, M., additional, Wang, M., additional, Siu, C. W., additional, Lee, K., additional, Yue, W. S., additional, Yan, G. H., additional, Lee, S., additional, Lau, C. P., additional, Tse, H. F., additional, O'connor, K., additional, Rosca, M., additional, Magne, J., additional, Romano, G., additional, Moonen, M., additional, Pierard, L. A., additional, Lancellotti, P., additional, Floria, M., additional, De Roy, L., additional, Blommaert, D., additional, Jamart, J., additional, Dormal, F., additional, Lacrosse, M., additional, Arsenescu Georgescu, C., additional, Mizariene, V., additional, Bucyte, S., additional, Bertasiute, A., additional, Pociute, E., additional, Zaliaduonyte-Peksiene, D., additional, Baronaite-Dudoniene, K., additional, Sileikiene, R., additional, Vaskelyte, J., additional, Jurkevicius, R., additional, Dencker, M., additional, Thorsson, O., additional, Karlsson, M. K., additional, Linden, C., additional, Wollmer, P., additional, Andersen, L. B., additional, Catalano, O., additional, Perotti, M. R., additional, Colombo, E., additional, De Giorgi, M., additional, Cattaneo, M., additional, Cobelli, F., additional, Priori, S. G., additional, Ober, C., additional, Iancu Adrian, I. A., additional, Andreea Parv, P. A., additional, Cadis Horatiu, C. H., additional, Ober Mihai, O. M., additional, Chmielecki, M., additional, Fijalkowski, M., additional, Galaska, R., additional, Dubaniewicz, W., additional, Lewicki, L., additional, Targonski, R., additional, Ciecwierz, D., additional, Puchalski, W., additional, Koprowski, A., additional, Rynkiewicz, A., additional, Hristova, K., additional, La Gerche, A., additional, Katova, T. Z., additional, Kostova, V., additional, Simova, Y., additional, Kempny, A., additional, Diller, G. P., additional, Orwat, S., additional, Kaleschke, G., additional, Kerckhoff, G., additional, Schmidt, R., additional, Radke, R. M., additional, Baumgartner, H., additional, Smarz, K., additional, Zaborska, B., additional, Jaxa-Chamiec, T., additional, Maciejewski, P., additional, Budaj, A., additional, Kiotsekoglou, A., additional, Govind, S. C., additional, Gadiyaram, V., additional, Moggridge, J. C., additional, Govindan, M., additional, Gopal, A. S., additional, Ramesh, S. S., additional, Brodin, L. A., additional, Saha, S. K., additional, Ramzy, I. S., additional, Lindqvist, P., additional, Lam, Y. Y., additional, Duncan, A. M., additional, Henein, M. Y., additional, Craciunescu, I. S., additional, Serban, M., additional, Iancu, M., additional, Revnic, C., additional, Popescu, B. A., additional, Alexandru, D., additional, Rogoz, D., additional, Uscatescu, V., additional, Ginghina, C., additional, Careri, G., additional, Di Monaco, A., additional, Nerla, R., additional, Tarzia, P., additional, Lamendola, P., additional, Sestito, A., additional, Lanza, G. A., additional, Crea, F., additional, Giannini, F., additional, Pinamonti, B., additional, Santangelo, S., additional, Perkan, A., additional, Vitrella, G., additional, Rakar, S., additional, Merlo, M., additional, Della Grazia, E., additional, Salvi, A., additional, Sinagra, G., additional, Scislo, P., additional, Kochanowski, J., additional, Piatkowski, R., additional, Roik, M., additional, Postula, M., additional, Opolski, G., additional, Castillo, J., additional, Herszkowicz, N., additional, Ferreira, C., additional, Lonnebakken, M. T., additional, Staal, E. M., additional, Nordrehaug, J. E., additional, Gerdts, E., additional, Przewlocka-Kosmala, M., additional, Orda, A., additional, Karolko, B., additional, Bajraktari, G., additional, Gustafsson, U., additional, Holmgren, A., additional, Frattini, S., additional, Faggiano, P., additional, Zilioli, V., additional, Locantore, E., additional, Longhi, S., additional, Bellandi, F., additional, Faden, G., additional, Triggiani, M., additional, Dei Cas, L., additional, Seo, S. M., additional, Jung, H. O., additional, An, S. H., additional, Jung, S. Y., additional, Park, C. S., additional, Jeon, H. K., additional, Youn, H. J., additional, Chung, W. B., additional, Kim, J. H., additional, Uhm, J. S., additional, Mampuya, W., additional, Brochu, M. C., additional, Do, D. H., additional, Essadiqi, B., additional, Farand, P., additional, Lepage, S., additional, Daly, M. J., additional, Monaghan, M., additional, Hamilton, A., additional, Lockhart, C., additional, Kodoth, V., additional, Maguire, C., additional, Morton, A., additional, Manoharan, G., additional, Spence, M. S., additional, Streb, W., additional, Mitrega, K., additional, Nowak, J., additional, Duszanska, A., additional, Szulik, M., additional, Kalinowski, M., additional, Kukulski, T., additional, Kalarus, Z., additional, Calvo Iglesias, F. E., additional, Solla-Ruiz, I., additional, Villanueva-Benito, I., additional, Paredes-Galan, E., additional, Bravo-Amaro, M., additional, Iniguez-Romo, A., additional, Yildirimturk, O., additional, Helvacioglu, F. F., additional, Tayyareci, Y., additional, Yurdakul, S., additional, Demiroglu, I. C., additional, Aytekin, S., additional, Enache, R., additional, Piazza, R., additional, Muraru, D., additional, Roman-Pognuz, A., additional, Calin, A., additional, Leiballi, E., additional, Antonini-Canterin, F., additional, Nicolosi, G. L., additional, Ridard, C., additional, Bellouin, A., additional, Thebault, C., additional, Laurent, M., additional, Donal, E., additional, Sutandar, A., additional, Siswanto, B. B., additional, Irmalita, I., additional, Harimurti, G., additional, Saxena, A., additional, Ramakrishnan, S., additional, Roy, A., additional, Krishnan, A., additional, Misra, P., additional, Bhargava, B., additional, Poole-Wilson, P. A., additional, Loegstrup, B. B., additional, Andersen, H. R., additional, Poulsen, S. H., additional, Klaaborg, K. E., additional, Egeblad, H. E., additional, Gu, X., additional, Gu, X. Y., additional, He, Y. H., additional, Li, Z. A., additional, Han, J. C., additional, Chen, J., additional, Mansencal, N., additional, Mitry, E., additional, Rougier, P., additional, Dubourg, O., additional, Villarraga, H., additional, Adjei-Twum, K., additional, Cudjoe, T. K. M., additional, Clavell, A., additional, Schears, R. M., additional, Cabrera Bueno, F., additional, Molina Mora, M. J., additional, Fernandez Pastor, J., additional, Linde Estrella, A., additional, Pena Hernandez, J. L., additional, Isasti Aizpurua, G., additional, Carrasco Chinchilla, F., additional, Barrera Cordero, A., additional, Alzueta Rodriguez, F. J., additional, De Teresa Galvan, E., additional, Gaetano Contegiacomo, G. C., additional, Francesco Pollice, F. P., additional, Paolo Pollice, P. P., additional, Kontos, M. C., additional, Shin, D. H., additional, Yoo, S. Y., additional, Lee, C. K., additional, Jang, J. K., additional, Jung, S. I., additional, Song, S. I., additional, Seo, S. I., additional, Cheong, S. S., additional, Peteiro, J., additional, Perez-Perez, A., additional, Bouzas-Mosquera, A., additional, Pineiro, M., additional, Pazos, P., additional, Campo, R., additional, Castro-Beiras, A., additional, Gaibazzi, N., additional, Rigo, F., additional, Sartorio, D., additional, Reverberi, C., additional, Sitia, S., additional, Tomasoni, L., additional, Gianturco, L., additional, Ghio, L., additional, Stella, D., additional, Greco, P., additional, De Gennaro Colonna, V., additional, Turiel, M., additional, Cicala, S., additional, Magagnin, V., additional, Caiani, E., additional, Kyrzopoulos, S., additional, Tsiapras, D., additional, Domproglou, G., additional, Avramidou, E., additional, Voudris, V., additional, Wierzbowska-Drabik, K., additional, Lipiec, P., additional, Chrzanowski, L., additional, Roszczyk, N., additional, Kupczynska, K., additional, Kasprzak, J. D., additional, Sachpekidis, V., additional, Bhan, A., additional, Gianstefani, S., additional, Reiken, J., additional, Paul, M., additional, Pearson, P., additional, Harries, D., additional, Monaghan, M. J., additional, Dale, K., additional, Stoylen, A., additional, Kodali, V., additional, Toole, R., additional, Raju, P., additional, Mcintosh, R. A., additional, Silberbauer, J., additional, Baumann, O., additional, Patel, N. R., additional, Sulke, N., additional, Trivedi, U., additional, Hyde, J., additional, Venn, G., additional, Lloyd, G., additional, Wejner-Mik, P., additional, Wierzbowska, K., additional, Lowenstein, J. A., additional, Caniggia, C., additional, Garcia, A., additional, Amor, M., additional, Casso, N., additional, Lowenstein Haber, D., additional, Porley, C., additional, Zambrana, G., additional, Daru, V., additional, Deljanin Ilic, M., additional, Ilic, S., additional, Kalimanovska Ostric, D., additional, Stoickov, V., additional, Zdravkovic, M., additional, Paraskevaidis, I., additional, Ikonomidis, I., additional, Parissis, J., additional, Papadopoulos, C., additional, Stasinos, V., additional, Bistola, V., additional, Anastasiou-Nana, M., additional, Gudin Uriel, M., additional, Balaguer Malfagon, J. R., additional, Perez Bosca, J. L., additional, Ridocci Soriano, F., additional, Martinez Alzamora, N., additional, Paya Serrano, R., additional, Ciampi, Q., additional, Pratali, L., additional, Della Porta, M., additional, Petruzziello, B., additional, Villari, B., additional, Picano, E., additional, Sicari, R., additional, Rosner, A., additional, Avenarius, D., additional, Malm, S., additional, Iqbal, A., additional, Baltabaeva, A., additional, Sutherland, G. R., additional, Bijnens, B., additional, Myrmel, T., additional, Andersen, M., additional, Gustafsson, F., additional, Secher, N. H., additional, Brassard, P., additional, Jensen, A. S., additional, Hassager, C., additional, Madsen, P. L., additional, Moller, J. E., additional, Coutu, M., additional, Greentree, D., additional, Normandin, D., additional, Brun, H., additional, Dipchand, A., additional, Koopman, L., additional, Fackoury, C. T., additional, Truong, S., additional, Manlhiot, C., additional, Mertens, L., additional, Baroni, M., additional, Mariani, M., additional, Chabane, H. K., additional, Berti, S., additional, Ripoli, A., additional, Storti, S., additional, Glauber, M., additional, Scopelliti, P. A., additional, Antongiovanni, G. B., additional, Personeni, D., additional, Saino, A., additional, Tespili, M., additional, Jung, P., additional, Mueller, M., additional, Jander, F., additional, Sohn, H. Y., additional, Rieber, J., additional, Schneider, P., additional, Klauss, V., additional, Agricola, E., additional, Slavich, M., additional, Stella, S., additional, Ancona, M., additional, Oppizzi, M., additional, Bertoglio, L., additional, Melissano, G., additional, Margonato, A., additional, Chiesa, R., additional, Cejudo Diaz Del Campo, L., additional, Mesa Rubio, D., additional, Ruiz Ortiz, M., additional, Delgado Ortega, M., additional, Villanueva Fernandez, E., additional, Lopez Aguilera, J., additional, Toledano Delgado, F., additional, Pan Alvarez-Ossorio, M., additional, Suarez De Lezo Cruz Conde, J., additional, Lafuente, M., additional, Butz, T., additional, Meissner, A., additional, Lang, C. N., additional, Prull, M. W., additional, Plehn, G., additional, Trappe, H. J., additional, Nair, S. V., additional, Lee, L., additional, Mcleod, I., additional, Whyte, G., additional, Shrimpton, J., additional, Hildick Smith, D., additional, James, P. R., additional, Slikkerveer, J., additional, Appelman, Y. E. A., additional, Veen, G., additional, Porter, T. R., additional, Kamp, O., additional, Colonna, P., additional, Ten Cate, F. J., additional, Bokor, D., additional, Daponte, A., additional, Cocciolo, M., additional, Bona, M., additional, Sacchi, S., additional, Becher, H., additional, Chai, S. C., additional, Tan, P. J., additional, Goh, Y. S., additional, Ong, S. H., additional, Chow, J., additional, Lee, L. L., additional, Goh, P. P., additional, Tong, K. L., additional, Kakihara, R., additional, Naruse, C., additional, Hironaka, H., additional, Tsuzuku, T., additional, Ozawa, K., additional, Tomaszuk-Kazberuk, A., additional, Sobkowicz, B., additional, Malyszko, J., additional, Malyszko, J. S., additional, Sawicki, R., additional, Hirnle, T., additional, Dobrzycki, S., additional, Mysliwiec, M., additional, Musial, W. J., additional, Mathias, W., additional, Kowatsch, I., additional, Saroute, A. L. R., additional, Osorio, A. F. F., additional, Sbano, J. C. N., additional, Ramires, J. A. F., additional, Tsutsui, J. M., additional, Sakata, K., additional, Ito, H., additional, Ishii, K., additional, Sakuma, T., additional, Iwakura, K., additional, Yoshino, H., additional, Yoshikawa, J., additional, Shahgaldi, K., additional, Lopez, A., additional, Fernstrom, B., additional, Sahlen, A., additional, Winter, R., additional, Kovalova, S., additional, Necas, J., additional, Amundsen, B. H., additional, Jasaityte, R., additional, Kiss, G., additional, Barbosa, D., additional, D'hooge, J., additional, Torp, H., additional, Szmigielski, C. A., additional, Newton, J. D., additional, Rajpoot, K., additional, Noble, J. A., additional, Kerber, R., additional, Koopman, L. P., additional, Slorach, C., additional, Chahal, N., additional, Hui, W., additional, Sarkola, T., additional, Bradley, T. J., additional, Jaeggi, E. T., additional, Mccrindle, B. W., additional, Staron, A., additional, Jasinski, M., additional, Wos, S., additional, Sengupta, P., additional, Hayat, D., additional, Kloeckner, M., additional, Nahum, J., additional, Dussault, C., additional, Dubois Rande, J. L., additional, Gueret, P., additional, Lim, P., additional, King, G. J., additional, Brown, A., additional, Ho, E., additional, Amuntaser, I., additional, Bennet, K., additional, Mc Elhome, N., additional, Murphy, R. T., additional, Cooper, R. M., additional, Somauroo, J. D., additional, Shave, R. E., additional, Williams, K. L., additional, Forster, J., additional, George, C., additional, Bett, T., additional, George, K. P., additional, D'andrea, A., additional, Riegler, L., additional, Cocchia, R., additional, Golia, E., additional, Gravino, R., additional, Salerno, G., additional, Citro, R., additional, Caso, P. I. O., additional, Bossone, E., additional, Calabro', R., additional, Crispi, F., additional, Figueras, F., additional, Bartrons, J., additional, Eixarch, E., additional, Le Noble, F., additional, Ahmed, A., additional, Gratacos, E., additional, Shang, Q., additional, Yip, W. K., additional, Tam, L. S., additional, Zhang, Q., additional, Li, C. M., additional, Wang, T., additional, Ma, C. Y., additional, Li, K. M., additional, Yu, C. M., additional, Dahlslett, T., additional, Helland, I., additional, Edvardsen, T., additional, Skulstad, H., additional, Magda, L. S., additional, Florescu, M., additional, Ciobanu, A., additional, Dulgheru, R., additional, Mincu, R., additional, Vinereanu, D., additional, Luckie, M., additional, Chacko, S., additional, Nair, S., additional, Mamas, M., additional, Khattar, R. S., additional, El-Omar, M., additional, Kuch-Wocial, A., additional, Pruszczyk, P., additional, Szulc, M., additional, Styczynski, G., additional, Sinski, M., additional, Kaczynska, A., additional, Vela, Z., additional, Haliti, E., additional, Hyseni, V., additional, Olloni, R., additional, Rexhepaj, N., additional, Elezi, S., additional, Onaindia, J. J., additional, Quintana, O., additional, Cacicedo, A., additional, Velasco, S., additional, Alarcon, J. J., additional, Morillas, M., additional, Rumoroso, J. R., additional, Zumalde, J., additional, Lekuona, I., additional, Laraudogoitia Zaldumbide, E., additional, Poniku, A., additional, Ahmeti, A., additional, Duncan, R. F., additional, Mccomb, J. M., additional, Pemberton, J., additional, Lord, S. W., additional, Leong, D., additional, Plummer, C., additional, Macgowan, G., additional, Grubb, N., additional, Leung, M., additional, Kenny, A., additional, Prinz, C., additional, Voigt, J. U., additional, Zaidi, A., additional, Heatley, M., additional, Abildstrom, S. Z., additional, Hvelplund, A., additional, Berning, J., additional, Govind, S., additional, Brodin, L., additional, Gopal, A., additional, Castaldi, B., additional, Di Salvo, G., additional, Santoro, G., additional, Gaio, G., additional, Palladino, M. T., additional, Iacono, C., additional, Pacileo, G., additional, Russo, M. G., additional, Calabro, R., additional, Wang, Y. S., additional, Dong, L. L., additional, Shu, X. H., additional, Pan, C. Z., additional, Zhou, D. X., additional, Sen, T., additional, Tufekcioglu, O., additional, Ozdemir, M., additional, Tuncez, A., additional, Uygur, B., additional, Golbasi, Z., additional, Kisacik, H., additional, Delfino, L., additional, De Leo, F. D., additional, Chiappa, L. C., additional, Abdel Ghani, B., additional, Schiavina, R., additional, Salvade, P., additional, Morganti, A., additional, Bedogni, F., additional, Mahia, P., additional, Gutierrez, L., additional, Pineda, V., additional, Garcia, B., additional, Otaegui, I., additional, Rodriguez, J. F., additional, Gonzalez, M. T., additional, Descalzo, M., additional, Evangelista, A., additional, Garcia-Dorado, D., additional, Bruin De- Bon, H. A. C. M., additional, Van Den Brink, R. B. A., additional, Surie, S., additional, Bresser, P., additional, Vleugels, J., additional, Eckmann, H. M., additional, Samson, D. A., additional, Bouma, B. J., additional, Dedobbeleer, C., additional, Antoine, M., additional, Remmelink, M., additional, Unger, P., additional, Roosens, B., additional, Hmila, I., additional, Hernot, S., additional, Droogmans, S., additional, Van Camp, G., additional, Lahoutte, T., additional, Muyldermans, S., additional, Cosyns, B., additional, Feltes, G., additional, Serra, V., additional, Azevedo, O., additional, Barbado, J., additional, Herrera, J., additional, Rivera, A., additional, Paniagua, J., additional, Valverde, V., additional, Torras, J., additional, Arriba, G., additional, Christodoulides, T., additional, Ioannides, M., additional, Simamonian, K., additional, Yiangou, K., additional, Myrianthefs, M., additional, Nicolaides, E., additional, Pandolfo, M., additional, Kleijn, S. A., additional, Aly, M. F. A. A., additional, Terwee, C. B., additional, Van Rossum, A. C., additional, Delgado, V., additional, Shanks, M., additional, Siebelink, H. M., additional, Sieders, A., additional, Lamb, H., additional, Ajmone Marsan, N., additional, Westenberg, J., additional, De Roos, A., additional, Schuijf, J. D., additional, Bax, J. J., additional, Anwar, A. M., additional, Nosir, Y., additional, Chamsi-Pasha, H., additional, Tschernich, H. D., additional, Seeburger, J., additional, Borger, M., additional, Mukherjee, C., additional, Mohr, F. W., additional, Ender, J., additional, Obase, K., additional, Okura, H., additional, Yamada, R., additional, Miyamoto, Y., additional, Saito, K., additional, Imai, K., additional, Hayashida, A., additional, and Yoshida, K., additional

Published
2010
Full Text
View/download PDF

46. Feasibility of all-oral anti-HCV treatment during DHAP chemotherapy and autologous stem cell transplantation for T-cell lymphoma

Author

Rossotti, R., Rusconi, C., Baiguera, C., Zilioli, V. R., Grillo, G., Merli, M., Ravano, E., Massimo Puoti, Rossotti, R, Rusconi, C, Baiguera, C, Zilioli, V, Grillo, G, Merli, M, Ravano, E, and Puoti, M

Subjects
Adult, Male, HCV, Antineoplastic Combined Chemotherapy Protocols, Administration, Oral, Humans, T-cell lymphoma, Autologous stem cell transplantation, Middle Aged, Lymphoma, T-Cell, Antiviral Agents, Hepatitis C, DAA
Abstract

The role of anti-HCV direct-acting agents (DAAs) is well described in HCV-related lymphoproliferative disorders, whereas few data are available on their use in other Malignancies, such as aggressive T-cell lymphomas requiring autologous stem cell transplantation (ASCT). We describe two oncologic cirrhotic patients treated with DAAs who underwent ASCT achieving cure for both diseases. Co-administration of sofosbuvir with cisplatin led an unexpected severe kidney impairment that did not resolve 30 weeks after drug exposure. The optimal timing of DAA administration in the ASCT setting has yet to be defined: our experience shows that co-administration is feasible, but requires close monitoring for adverse events.

47. EFFECTIVENESS AND SAFETY OF IBRUTINIB IN RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA TREATED IN ITALY ACCORDING TO THE IBRUTINIB NAMED PATIENT PROGRAM: THE REAL LIFE RESULTS

Author

Morigi, A., Federico Sottotetti, Gotti, M., Spina, M., Volpetti, S., Ferrero, S., Spina, F., Pisani, F., Merli, M., Visco, C., Paolini, R., Zilioli, V. R., Baldini, L., Di Renzo, N., Tosi, P., Cascavilla, N., Molica, S., Ilariucci, F., Rigolin, G. M., D Alo, F., Vanazzi, A., Santambrogio, E., Marasca, R., Mastrullo, L., Castellino, C., Desabbata, G., Scortechini, I., Trentin, L., Morello, L., Argnani, L., and Zinzani, P. L.

48. Response-Adapted Postinduction Strategy in Patients With Advanced-Stage Follicular Lymphoma: The FOLL12 Study

Author

Silvia Bolis, Ilaria Del Giudice, Donato Mannina, Stefano Luminari, Jacopo Olivieri, Annalisa Arcari, Luigi Marcheselli, Simone Ferrero, Martina Manni, Francesca Ricci, S. Kovalchuk, Tetiana Skrypets, Caterina Stelitano, Anna Merli, Antonella Anastasia, Alessandra Tucci, Lucia Farina, Massimo Federico, M. Ladetto, Stephane Chauvie, Annalisa Chiarenza, Carola Boccomini, Luca Guerra, Fondazione Italiana Linfomi, Vincenzo Pavone, Annibale Versari, Federica Cavallo, Vittorio Ruggero Zilioli, Antonello Pinto, Caterina Patti, Alessandra Dondi, Sara Galimberti, Gloria Margiotta Casaluci, Luca Arcaini, Luminari, S, Manni, M, Galimberti, S, Versari, A, Tucci, A, Boccomini, C, Farina, L, Olivieri, J, Marcheselli, L, Guerra, L, Ferrero, S, Arcaini, L, Cavallo, F, Kovalchuk, S, Skrypets, T, Del Giudice, I, Chauvie, S, Patti, C, Stelitano, C, Ricci, F, Pinto, A, Margiotta Casaluci, G, Zilioli, V, Merli, A, Ladetto, M, Bolis, S, Pavone, V, Chiarenza, A, Arcari, A, Anastasia, A, Dondi, A, Mannina, D, and Federico, M

Subjects
Male, Oncology, Cancer Research, medicine.medical_specialty, Lymphoma, PET/CT, Follicular lymphoma, MEDLINE, follicular lymphoma, minimal residual disease, treatment, Text mining, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, In patient, Prospective Studies, Cyclophosphamide, Doxorubicin, Female, Follow-Up Studies, Induction Chemotherapy, Lymphoma, Follicular, Middle Aged, Prednisone, Prognosis, Rituximab, Survival Rate, Vincristine, business.industry, Advanced stage, Follicular, medicine.disease, PET, business, medicine.drug
Abstract

PURPOSE We compared 2 years of rituximab maintenance (RM) with a response-adapted postinduction approach in patients with follicular lymphoma who responded to induction immunochemotherapy. METHODS We randomly assigned treatment-naïve, advanced-stage, high-tumor burden follicular lymphoma patients to receive standard RM or a response-adapted postinduction approach on the basis of metabolic response and molecular assessment of minimal residual disease (MRD). The experimental arm used three types of postinduction therapies: for complete metabolic response (CMR) and MRD-negative patients, observation; for CMR and MRD-positive (end of induction or follow-up) patients, four doses of rituximab (one per week, maximum three courses) until MRD-negative; and for non-CMR patients, one dose of ibritumomab tiuxetan followed by standard RM. The study was designed as noninferiority trial with progression-free survival (PFS) as the primary end point. RESULTS Overall, 807 patients were randomly assigned. After a median follow-up of 53 months (range, 1-92 months), patients in the standard arm had a significantly better PFS than those in the experimental arm (3-year PFS 86% v 72%; P < .001). The better PFS of the standard versus experimental arm was confirmed in all the study subgroups except non-CMR patients (n = 65; P = .274). The 3-year overall survival was 98% (95% CI, 96 to 99) and 97% (95% CI, 95 to 99) in the reference and experimental arms, respectively ( P = .238). CONCLUSION A metabolic and molecular response-adapted therapy as assessed in the FOLL12 study was associated with significantly inferior PFS compared with 2-year RM. The better efficacy of standard RM was confirmed in the subgroup analysis and particularly for patients achieving both CMR and MRD-negative.

Published
2022

49. Current Treatment Options and the Role of Functional Status Assessment in Classical Hodgkin Lymphoma in Older Adults: A Review

Author

Vittorio Ruggero Zilioli, Cristina Muzi, Chiara Pagani, Emanuele Ravano, Erika Meli, Rosa Daffini, Erika Ravelli, Roberto Cairoli, Alessandro Re, Zilioli, V, Muzi, C, Pagani, C, Ravano, E, Meli, E, Daffini, R, Ravelli, E, Cairoli, R, and Re, A

Subjects
comorbidity, Cancer Research, Oncology, brentuximab vedotin, functional statu, geriatric assessment, MED/15 - MALATTIE DEL SANGUE, elderly, Hodgkin lymphoma
Abstract

Along with the fact that classical Hodgkin lymphoma (cHL) in older adults is frequently considered biologically different from cHL in younger patients, its most distinctive feature is its dismal clinical outcome due to the decreased effectiveness and greater toxicity of therapies. Although strategies to mitigate specific toxicities (e.g., cardiological and pulmonary) have obtained some results, in general, reduced-intensity schemes, proposed as an alternative to ABVD, have proved to be less effective. The addition of brentuximab vedotin (BV) to AVD, especially in a sequential scheme, has demonstrated good efficacy. However, the problem of toxicity persists even with this new therapeutic combination, with comorbidities remaining an important prognostic factor. The adequate stratification of functional status is necessary to distinguish between those patients who will benefit from full treatment and those who will benefit from alternative strategies. A simplified geriatric assessment based on the determination of ADL (activity of daily living), IADL (instrumental ADL), and CIRS-G (Cumulative Illness Rating Scale—Geriatric) scores is an easy-to-use tool that permits adequate patient stratification. Other factors of considerable impact on functional status such as sarcopenia and immunosenescence are currently being studied. A fitness-based treatment choice would also be very useful for relapsed or refractory patients, a more frequent and challenging situation than that is found in young cHL patients.

Published
2023

50. Role of radiotherapy to bulky sites of advanced Hodgkin lymphoma treated with ABVD: Final results of FIL HD0801 trial

Author

Alessandro Re, Luca Nassi, Armando Santoro, Daniela Gioia, Vittorio Ruggero Zilioli, Paola Franzone, Alessandro Pulsoni, Pier Luigi Zinzani, Luigi Rigacci, Monica Tani, Francesco Zaja, Mario Levis, Gabriele Simontacchi, Umberto Ricardi, Manuela Zanni, Antonio Nardella, Vincenzo Pavone, Michela Buglione, Andrea Riccardo Filippi, Delia Rota-Scalabrini, Manuel Gotti, Barbara Botto, Giovanni Frezza, Elisabetta Abruzzese, Gian Mauro Sacchetti, Lavinia Grapulin, Roberto Freilone, Giovannino Ciccone, Andrea Evangelista, Ricardi, U., Levis, M., Evangelista, A., Gioia, D. M., Sacchetti, G. M., Gotti, M., Re, A., Buglione, M., Pavone, V., Nardella, A., Nassi, L., Zanni, M., Franzone, P., Frezza, G. P., Pulsoni, A., Grapulin, L., Santoro, A., Rigacci, L., Simontacchi, G., Tani, M., Zaja, F., Abruzzese, E., Botto, B., Zilioli, V. R., Rota-Scalabrini, D., Freilone, R., Ciccone, G., Filippi, A. R., Zinzani, P. L., Ricardi U., Levis M., Evangelista A., Gioia D.M., Sacchetti G.M., Gotti M., Re A., Buglione M., Pavone V., Nardella A., Nassi L., Zanni M., Franzone P., Frezza G.P., Pulsoni A., Grapulin L., Santoro A., Rigacci L., Simontacchi G., Tani M., Zaja F., Abruzzese E., Botto B., Zilioli V.R., Rota-Scalabrini D., Freilone R., Ciccone G., Filippi A.R., and Zinzani P.L.

Subjects
Clinical Trials and Observations, Dacarbazine, Bleomycin, Vinblastine, law.invention, chemistry.chemical_compound, Randomized controlled trial, law, Antineoplastic Combined Chemotherapy Protocols, medicine, Clinical endpoint, Doxorubicin, Humans, Neoplasm Staging, Hodgkin Disease, Antineoplastic Combined Chemotherapy Protocol, business.industry, Hazard ratio, Hematology, Confidence interval, chemistry, ABVD, business, Nuclear medicine, medicine.drug, Human
Abstract

Key Points The prognosis of patients with advanced HL who achieved CMR after both 2 and 6 ABVD cycles is excellent without consolidation RT.An additional benefit of consolidation RT of sites >5 cm is likely to be small and could not be proved for this small sample size., Visual Abstract, The role of consolidation radiotherapy (RT) for bulky lesions is controversial in patients with advanced-stage Hodgkin lymphoma who achieve complete metabolic response (CMR) after doxorubicin, bleomycin, vinblastine, dacarbazine (ABVD)–based chemotherapy. We present the final results of the Fondazione Italiana Linfomi HD0801 trial, which investigated the potential benefit of RT in that setting. In this phase 3 randomized study, patients with a bulky lesion at baseline (a mass with largest diameter ≥5 cm) who have CMR after 2 and 6 ABVD cycles were randomly assigned 1:1 to RT vs observation (OBS) with a primary endpoint of event-free survival (EFS) at 2 years. The sample size was calculated estimating an EFS improvement for RT of 20% (from 60% to 80%). The secondary end point was progression-free survival (PFS). One hundred sixteen patients met the inclusion criteria and were randomly assigned to RT or OBS. Intention-to-treat (ITT) analysis showed a 2-year EFS of 87.8% vs 85.8% for RT vs OBS (hazard ratio [HR], 1.5; 95% confidence interval [CI], 0.6-3.5; P = .34). At 2 years, ITT-PFS was 91.3% vs 85.8% (HR, 1.2; 95% CI, 0.5-3; P = .7). Patients in CMR randomly assigned to OBS had a good outcome, and the primary end point of a 20% benefit in EFS for RT was not met. However, the sample size was underpowered to detect a benefit of 10% or less, keeping open the question of a potential, more limited role of RT in this setting. This trial was registered at www.clinicaltrials.gov as #NCT00784537.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results